CVM's failure is expected by many. The agent they tried Multikine has failed many times before for other cancer indication.
Despite its general failure for head and neck cancer, I do believe after all have settled down, they should get Multikine approved for those patients who receive Multikine followed by the part of SOC (surgery and radiotherapy only without chemo) because of reasonable improvement of OS plus quality of life for patients.
As for NWBO's DCVax-L, it's the first time DCVax-L is used in p3 clinical trial built up from positive p1/2 trial;
Most importantly, we know what the results would be look like from interim blinded, blended data published in 2018 on the backdrop of no improvement of SOC for GMB for decades and improvement data uptrend observed from the followed up data presentation after the publication.
Unless the final data readout is significantly worse than the data published in 2018 and/or placebo patients (or patients who received vaccine later after progression) outlive patients of treatment arm (or patients who received vaccine earlier before progression), it's no way DCVax-L will not show significant efficacy over SOC.
As I am typing, my first buy order is shown filled at 1.52. Intended to buy more as the price is artificially pulled down for obvious reason today: psychological impact for those ignorant due to CVM's failure, despite there is nothing comparable.
Besides, cvm ceo has spared no opportunities in pumping cvm stock while our dear ceo Linda has spared no opportunities keeping quiet.
[got a tiny order filled again at 1.51 as of 10:48am]
[Plus, cvm's large financing just last week or so was very suspicious]
[got this batch of order filled at 1.50]
[more to come]
